Gilead Sciences (GILD) PT Raised to $67 at BMO Capital

BMO Capital analyst Matthew Luchini raised the price target on Gilead Sciences (NASDAQ: GILD) to $67.00 while maintaining a Market Perform rating.

The analyst commented, "Gilead reported a top- and bottom-line beat driven by Veklury, though full year 2020 product sales of $24.4bn were at the top of January's revised guidance. 2021 guidance expects significant ($2-$3bn) Veklury contribution, though we expect sales to be front-end loaded. We continue to view Gilead's pipeline as improving but data takes time to unfold, and with guidance suggesting core (ex-Veklury) growth of ~2% at the mid-point we believe clinical and commercial executions remain key. Model updates for 4Q results and guidance increase our target to $67. Reiterate Market Perform."

You May Also Be Interested In

• The Campbell's Co. (CPB) PT Lowered to $20 at Jefferies, 'we remain cautious'
• CLSA Downgrades Heineken Malaysia Bhd (HEIM:MK) to Hold (3)
• CIENA (CIEN) PT Lowered to $375 at Evercore ISI